KR970073581A - 초로기성 알쯔하이머 질환 치료용 카르니틴 유도체 함유 의약품 - Google Patents
초로기성 알쯔하이머 질환 치료용 카르니틴 유도체 함유 의약품 Download PDFInfo
- Publication number
- KR970073581A KR970073581A KR1019970019692A KR19970019692A KR970073581A KR 970073581 A KR970073581 A KR 970073581A KR 1019970019692 A KR1019970019692 A KR 1019970019692A KR 19970019692 A KR19970019692 A KR 19970019692A KR 970073581 A KR970073581 A KR 970073581A
- Authority
- KR
- South Korea
- Prior art keywords
- carnitine
- acetyl
- pharmaceutically acceptable
- acceptable salts
- acid
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 10
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical class C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 230000005713 exacerbation Effects 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 208000024891 symptom Diseases 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 150000003893 lactate salts Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 알쯔하이머 질환 치료용 의약품 생산에 유용한 아세틸-L-카르니틴과 이의 약제학적으로 수용가능한 염의 용도에 관한 것으로, 더욱 상세하게는 알쯔하이머 질환의 조기 발현, 즉 초로기성 알쯔하이머 질환으로 고생하고 있는 환자들에게 전형적인 증상의 악화를 지연시킬 수 있는 의약품을 생산하는 데 유용한 상기 화합물의 용도에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- 초로기성(初老期性) 알쯔하이머 질환 증상 악화를 지연시키는 의약품 생산에 유용한 것임을 특징으로 하는 아세틸 L-카르니틴 및 이들의 약제학적으로 허용 가능한 염의 용도.
- 제1항에 있어서, 상기 의약품은 정신장애의 진단 및 통계학적 편람[4th Ed., 개정판(DSM-Ⅳ-R), 미국 정신병학회]에 준한 '초로기성(初老期性) 알쯔하이머 환자'라고 정의되는 환자의 치료에 유용한 것 중에서 선택한 것임을 특징으로 하는 아세틸 L-카르니틴 및 이들의 약제학적으로 허용 가능한 염의 용도.
- 제2항에 있어서, 상기 의약품은 초로기성(初老期性) 알쯔하이머 환자의 첫번째 종점(終點)의 악화를 지연시키는데 유용한 것 중에서 선택한 것임을 특징으로 하는 아세틸 L-카르니틴 및 이들의 약제학적으로 허용 가능한 염의 용도.
- 제2항에 있어서, 상기 의약품은 초로기성(初老期性) 알쯔하이머 환자의 ADAS-Cog 및 CDR의 악화를 지연시키는데 유용한 것 중에서 선택한 것임은 특징으로 하는 아세틸 L-카르니틴 및 이들의 약제학적으로 허용 가능한 염의 용도.
- 제1항 내지 제4항에 있어서, 상기 의약품은 경구 투여하는 것임을 특징으로 하는 아세틸 L-카르니틴 및 이들의 약제학적으로 허용 가능한 염의 용도.
- 제1항 내지 제4항에 있어서, 상기 의약품은 비경구 투여하는 것임을 특징으로 하는 아세틸 L-카르니틴 및 이들의 약제학적으로 허용 가능한 염의 용도.
- 제6항에 있어서, 상기 의약품은 정맥내 투여하는 것임을 특징으로 하는 아세틸 L-카르니틴 및 이들의 약제학적으로 허용 가능한 염의 용도.
- 제1항 내지 제7항 중 어느 한 항에 있어서, 아세틸 L-카르니틴의 약제학적으로 허용 가능한 염은 클로라이드, 브로마이드, 오로테이트, 엑시드 아스파테이트, 시트르산, 엑시드 포스레이트, 푸마레이트, 엑시드 푸마레이트, 락테이트, 말레에이트, 엑시드 말레에이트, 엑시드 옥살레이트, 엑시드 설페이트, 글루코오스 포스페이트, 타르트레이트 및 엑시드 타르트레이트 중에서 선택된 것임을 특징으로 하는 아세틸 L-카르니틴 및 이들의 약제학적으로 허용 가능한 염의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96RM000360A IT1284650B1 (it) | 1996-05-24 | 1996-05-24 | Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia |
| ITRM96A00360 | 1996-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970073581A true KR970073581A (ko) | 1997-12-10 |
Family
ID=11404242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970019692A KR970073581A (ko) | 1996-05-24 | 1997-05-21 | 초로기성 알쯔하이머 질환 치료용 카르니틴 유도체 함유 의약품 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0808626A1 (ko) |
| JP (1) | JPH1045582A (ko) |
| KR (1) | KR970073581A (ko) |
| CA (1) | CA2205940A1 (ko) |
| IT (1) | IT1284650B1 (ko) |
| MX (1) | MX9703810A (ko) |
| TW (1) | TW473388B (ko) |
| ZA (1) | ZA974506B (ko) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1276253B1 (it) | 1995-12-15 | 1997-10-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| ES2323940T3 (es) | 2000-05-01 | 2009-07-28 | Accera, Inc. | Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer. |
| US8173618B2 (en) * | 2003-07-25 | 2012-05-08 | University Of Massachusetts | Formulations for reducing neuronal degeneration |
| EP2500017B1 (en) | 2006-04-03 | 2017-09-06 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
| PT2650380E (pt) | 2007-07-31 | 2016-01-14 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
| US8597640B2 (en) | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
| US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| CA2729622C (en) | 2008-07-03 | 2017-07-25 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| SG185692A1 (en) * | 2010-06-16 | 2013-01-30 | Sigma Tau Ind Farmaceuti | Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue |
| EP2586438A1 (en) | 2011-10-28 | 2013-05-01 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Compound useful for preventing cognitive deficit disorders in a new born from HIV-seropositive pregnant female who is in treatment with azidothymidine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| EP0340759A1 (en) * | 1988-05-06 | 1989-11-08 | MAGIS FARMACEUTICI S.p.A. | Salts of O-mono (di)-acetyl-glycero-mono-(bis)-(di)-phosphates of L-acetyl-carnitine and of L-acetyl carnitine esters |
-
1996
- 1996-05-24 IT IT96RM000360A patent/IT1284650B1/it active IP Right Grant
- 1996-10-16 EP EP96830532A patent/EP0808626A1/en not_active Withdrawn
-
1997
- 1997-02-21 TW TW086102135A patent/TW473388B/zh active
- 1997-05-21 KR KR1019970019692A patent/KR970073581A/ko not_active Application Discontinuation
- 1997-05-23 MX MX9703810A patent/MX9703810A/es unknown
- 1997-05-23 CA CA002205940A patent/CA2205940A1/en not_active Abandoned
- 1997-05-23 JP JP9133289A patent/JPH1045582A/ja active Pending
- 1997-05-23 ZA ZA9704506A patent/ZA974506B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT1284650B1 (it) | 1998-05-21 |
| EP0808626A1 (en) | 1997-11-26 |
| JPH1045582A (ja) | 1998-02-17 |
| ITRM960360A1 (it) | 1997-11-24 |
| ITRM960360A0 (it) | 1996-05-24 |
| CA2205940A1 (en) | 1997-11-24 |
| MX9703810A (es) | 1998-04-30 |
| ZA974506B (en) | 1997-12-29 |
| TW473388B (en) | 2002-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970073581A (ko) | 초로기성 알쯔하이머 질환 치료용 카르니틴 유도체 함유 의약품 | |
| CA2187990A1 (en) | Pharmaceutical compositions comprising l-carnitine, or derivative thereof, and trihydroxy or tetrahydroxystilbene | |
| WO2008137923A2 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders | |
| PT796103E (pt) | Utilizacao de incenso para tratamento da doenca de alzheimer | |
| MXPA06006811A (es) | Composicion de pregabalina. | |
| KR940006576A (ko) | 에이즈 및 에이즈 관련 증후군 환자 및 무증후성 hiv혈청양성 환자치료를 위한 l-카르니틴 및 아실 l-카르니틴의 용도 | |
| JP2005523269A5 (ko) | ||
| US5173508A (en) | Pharmaceutical compositions active on the cardiovascular system, containing 3-methylthiopropionyl l-carnitine | |
| US4771075A (en) | Use of acetyl L-carnitine for the therapeutical treatment of shock conditions | |
| PT1174131E (pt) | Utilização de um agente que melhora a função dos astrocitos para o tratamento da doença de parkinson | |
| Sweet et al. | Methyldopa as an adjunct to levodopa treatment of Parkinson's disease | |
| JP2000515156A (ja) | 精神病的疾患の治療 | |
| JP2008143856A (ja) | 非ステロイド系抗炎症剤配合医薬 | |
| RU2001119623A (ru) | Способ снижения содержания церамидов, набор, включающий антиретровирусное лекарственное средство | |
| CA2465471A1 (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction | |
| JP2008505134A5 (ko) | ||
| SK287832B6 (sk) | Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. | |
| JP2004532866A5 (ko) | ||
| US6214884B1 (en) | Composition comprising ketanserin and L-carnitine or an alkanoyl L-carnitine for the treatment of CRPS | |
| CA2400959A1 (en) | Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10 | |
| KR920703067A (ko) | 말초 신경질환 및 뇌질환 치료용 L-α-글리세로포르포릴-D-미오-이노시톨 | |
| CA2448242A1 (en) | Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain | |
| JP2004532865A5 (ko) | ||
| Calabro | Pharmacokinetics and clinical indications of sustained-release indomethacin | |
| HRP20120178T1 (hr) | Upotreba l-karnitina u liječenju kardiovaskularnih bolesti |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |